Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 1.045
1.
  • Rituximab for IgG4-related disease: a prospective, open-label trial
    Carruthers, Mollie N; Topazian, Mark D; Khosroshahi, Arezou ... Annals of the rheumatic diseases, 06/2015, Letnik: 74, Številka: 6
    Journal Article
    Recenzirano

    To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) in an open-label pilot trial. We treated 30 IgG4-RD patients with two doses of RTX (1000 mg each). The participants were ...
Celotno besedilo
Dostopno za: CMK, NUK, UL, UM, UPUK
2.
  • SYK Inhibition Modulates Di... SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas
    Chen, Linfeng; Monti, Stefano; Juszczynski, Przemyslaw ... Cancer cell, 06/2013, Letnik: 23, Številka: 6
    Journal Article
    Recenzirano
    Odprti dostop

    B cell receptor (BCR) signaling pathway components represent promising treatment targets in diffuse large B cell lymphoma (DLBCL) and additional B cell tumors. BCR signaling activates spleen tyrosine ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
3.
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
4.
  • Addition of Lenalidomide to... Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
    Nowakowski, Grzegorz S; Hong, Fangxin; Scott, David W ... Journal of clinical oncology, 04/2021, Letnik: 39, Številka: 12
    Journal Article
    Recenzirano
    Odprti dostop

    Lenalidomide combined with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (R2CHOP) in untreated diffuse large B-cell lymphoma (DLBCL) has shown promising activity, ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
5.
  • Single-Agent Lenalidomide i... Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
    GOY, Andre; SINHA, Rajni; WILLIAMS, Michael E ... Journal of clinical oncology, 10/2013, Letnik: 31, Številka: 29
    Journal Article
    Recenzirano
    Odprti dostop

    Although dose-intensive strategies or high-dose therapy induction followed by autologous stem-cell transplantation have improved the outcome for patients with mantle-cell lymphoma (MCL), most ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
6.
  • Acalabrutinib for mantle ce... Acalabrutinib for mantle cell lymphoma
    Witzig, Thomas E.; Inwards, David Blood, 06/2019, Letnik: 133, Številka: 24
    Journal Article
    Recenzirano
    Odprti dostop

    Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP

PDF
7.
  • Diagnosis-to-Treatment Inte... Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
    Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K ... Journal of clinical oncology, 06/2018, Letnik: 36, Številka: 16
    Journal Article
    Recenzirano
    Odprti dostop

    Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
8.
  • Early event status informs ... Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
    Maurer, Matthew J.; Bachy, Emmanuel; Ghesquières, Hervé ... American journal of hematology, November 2016, Letnik: 91, Številka: 11
    Journal Article
    Recenzirano
    Odprti dostop

    Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 and 24 months from ...
Celotno besedilo
Dostopno za: BFBNIB, FZAB, GIS, IJS, KILJ, NLZOH, NUK, OILJ, SAZU, SBCE, SBMB, UL, UM, UPUK

PDF
9.
  • Rates and Outcomes of Folli... Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource
    LINK, Brian K; MAURER, Matthew J; COLGAN, Joseph P ... Journal of clinical oncology, 09/2013, Letnik: 31, Številka: 26
    Journal Article
    Recenzirano
    Odprti dostop

    Purpose This study sought to characterize transformation incidence and outcome for patients with follicular lymphoma (FL) in a prospective observational series begun after diffusion of rituximab use. ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
10.
  • Peripheral blood lymphocyte... Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma
    PORRATA, Luis F; RISTOW, Kay; THOMPSON, Carrie ... Haematologica, 02/2012, Letnik: 97, Številka: 2
    Journal Article
    Recenzirano
    Odprti dostop

    Lymphopenia and tumor-associated macrophages are negative prognostic factors for survival in classical Hodgkin's lymphoma. We, therefore, studied whether the peripheral blood absolute lymphocyte ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
1 2 3 4 5
zadetkov: 1.045

Nalaganje filtrov